bpc-157 mechanism of action tissue healing Peptide Therapy for Inflammation: A New Solution Musculoskeletal and Tissue Healing with

To date, no severe adverse effects have been consistently documented in research settings

SS-31 (Elamipretide): The First FDA-Approved Mitochondrial Therapeutic In September 2025, the FDA granted accelerated approval to Forzinity (elamipretide), marking a watershed moment in mitochondrial medicine

This route offers easier execution, reduced discomfort, and adequate systemic distribution for most applications

At Better Med Spa in Lincoln Park, we see Synapse fitting into several patient profiles: Brain fog and cognitive fatigue

To understand the long-term safety and chronic effectiveness of these treatments, these studies will be essential

Clinical evidence remains limited and outcomes vary by patient